ClinicalTrials.Veeva

Menu

DC Vaccine Combined With CIK Cells in Patients With Renal Cell Carcinoma

A

Affiliated Hospital to Academy of Military Medical Sciences

Status and phase

Unknown
Phase 2
Phase 1

Conditions

Renal Cell Carcinoma

Treatments

Biological: adenovirus-transfected DC + CIK

Study type

Interventional

Funder types

Other

Identifiers

NCT01924156
307-CTC-DC/CIK-RCC

Details and patient eligibility

About

The aim of this Phase I/II study is to evaluate the safety and efficacy of dendritic cells (DC) vaccine combined with cytokine-induced killer (CIK) cells in patients with renal cell carcinoma. Experimental recombinant adenovirus-transfected DC, which engineered to express MUC1 and Survivin are used for DC-based immunotherapy. Based on the results of our previously performed preclinical study with DC vaccine combined with CIK cells, the investigators plan to perform the clinical trial.

Enrollment

30 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Age >18 years at time of consent
  • Histopathologically confirmed diagnosis of renal cell carcinoma
  • Received standardized treatment of renal cell carcinoma
  • Interval between the last standardized treatment and DC/CIK treatment ≥ 4weeks
  • KPS (Karnofsky performance scale) >60
  • Patient's written informed consent
  • Predicted survival >3 months
  • No severe viral or bacterial infections

Exclusion criteria

  • Receiving chemotherapy, radiotherapy or other therapy
  • Patients with other malignancies and infectious diseases
  • Pregnant and breast-feeding patient
  • Currently participating in another clinical trial
  • Unfit for participating in this clinical trial in investigators' opinions

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

30 participants in 1 patient group

adenovirus-transfected DC + CIK
Experimental group
Description:
adenovirus-transfected autologous DC vaccine plus CIK cells
Treatment:
Biological: adenovirus-transfected DC + CIK

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems